Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 11/20 | 0.49 |
| ▸ | CA1 | P00915 | 10/20 | 0.49 |
| ▸ | ACHE | P22303 | 1/20 | 0.49 |
| ▸ | CA9 | Q16790 | 10/20 | 0.47 |
| ▸ | CA12 | O43570 | 2/20 | 0.47 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.42 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.41 |
| ▸ | P2RX2 | Q9UBL9 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3511751 | 0.82 | L3MBTL1 (0.47) | CA2CA1ACHECA9CA12 | |
| SCHEMBL27905121 | 0.81 | SLC22A6 (0.42) | CA2CA1ACHEGABRA1GABRB2 | |
| SCHEMBL9451267 | 0.79 | CA2 (0.61) | CA2CA1CA9 | |
| SCHEMBL4875993 | 0.78 | CA1 (0.45) | CA2CA1CA9CA12 | |
| SCHEMBL4225144 | 0.77 | HSD11B1 (0.41) | CA2CA1ACHEGABRA1GABRB2 | |
| SCHEMBL28595222 | 0.74 | MEN1 (0.56) | GAA | |
| SCHEMBL3372383 | 0.74 | CA2 (0.52) | CA2CA1CA9GAA | |
| SCHEMBL9451230 | 0.74 | CA2 (0.56) | CA2CA1ACHECA9CA12 | |
| SCHEMBL4621913 | 0.73 | ALDH1A1 (0.52) | CA2CA1CA9CA12L3MBTL1 | |
| SCHEMBL17465920 | 0.73 | GAA (0.61) | CA2CA1CA9CA12GABRA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3790886-B1 | KRAS G12C INHIBITORS FOR THE TREATMENT OF CANCER | AMGEN INC (US) | 2024-06-26 | — | — | EP | disclosed |
| US-10988485-B2 | KRAS G12C inhibitors and methods of using the same | AMGEN INC. (US) | 2021-04-27 | — | — | US | disclosed |
| EP-3790886-A1 | KRAS G12C INHIBITORS FOR THE TREATMENT OF CANCER | Amgen Inc. (US) | 2021-03-17 | — | — | EP | disclosed |
| US-20190345169-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | AMGEN INC. | 2019-11-14 | — | — | US | disclosed |
| WO-2019217691-A1 | KRAS G12C INHIBITORS FOR THE TREATMENT OF CANCER | AMGEN INC. (US) | 2019-11-14 | — | — | WO | disclosed |
| US-9770711-B2 | General catalyst for C-H functionalization | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2017-09-26 | — | — | US | disclosed |
| US-9770711-B2 | General catalyst for C-H functionalization | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2017-09-26 | — | — | US | disclosed |
| US-9770711-B2 | General catalyst for C-H functionalization | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2017-09-26 | — | — | US | disclosed |
| US-20160272662-A1 | GENERAL CATALYST FOR C-H FUNCTIONALIZATION | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2016-09-22 | — | — | US | disclosed |
| US-20160272662-A1 | GENERAL CATALYST FOR C-H FUNCTIONALIZATION | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2016-09-22 | — | — | US | disclosed |
| US-20160272662-A1 | GENERAL CATALYST FOR C-H FUNCTIONALIZATION | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2016-09-22 | — | — | US | disclosed |
| US-20080096922-A1 | Novel Sulfonamide derivative | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2008-04-24 | — | — | US | disclosed |
| EP-1736467-A1 | NOVEL SULFONAMIDE DERIVATIVE | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2006-12-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080096922-A1 | Novel Sulfonamide derivative | NR4A1, NR4A2, NR4A3 | CA2 1381/4885CA1 2639/4885ACHE 4798/4885 |
| US-20160272662-A1 | GENERAL CATALYST FOR C-H FUNCTIONALIZATION | BET1, PLEC, NUDC | CA2 1192/4885CA1 555/4885ACHE 3143/4885 |
| US-20190345169-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | KRAS, NRAS, HRAS | CA2 2465/4885CA1 2659/4885ACHE 4824/4885 |
| US-10988485-B2 | KRAS G12C inhibitors and methods of using the same | KRAS, NRAS, HRAS | CA2 2465/4885CA1 2659/4885ACHE 4824/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.